23.17

4.23% 0.9399

After Hours: 23.17 0.0001 +0.00%

Vtv Therapeutics Inc (VTVT)

Overview News Price History Financials Discussions Forecast

Vtv Therapeutics Inc stock is traded at $23.17, with a volume of 2,832. It is up +4.23% in the last 24 hours and up +33.54% over the past month. vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

Previous Close:

$22.23

Open:

$22.28

24h Volume:

2,832

Relative Volume:

0.13

Market Cap:

$51.38M

Revenue:

$5.02M

Net Income/Loss:

$-18.31M

P/E Ratio:

-5.1148

EPS:

-4.53

Net Cash Flow:

$-23.40M

1W Performance:

+17.79%

1M Performance:

+33.54%

6M Performance:

+56.98%

1Y Performance:

-14.07%

1-Day Range:

$22.28

$23.20

1-Week Range:

$18.89

$23.20

52-Week Range:

$12.12

$29.19

Vtv Therapeutics Inc Stock (VTVT) Company Profile

Name

Vtv Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (673)

Phone

336-841-0300

Address

3980 PREMIER DR, HIGH POINT, NC

Employee

Twitter

@vTvTherapeutics

Next Earnings Date

2024-11-07

Latest SEC Filings

VTVT's Discussions on Twitter

Compare VTVT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTVT Vtv Therapeutics Inc	23.17	51.38M	5.02M	-18.31M	-23.40M	-4.53
VRTX Vertex Pharmaceuticals Inc	496.49	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.86	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	620.97	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	254.85	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.46	24.70B	3.81B	-644.79M	-669.77M	-6.24

Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-30-19	Initiated	H.C. Wainwright	Buy
Apr-10-18	Downgrade	Stifel	Buy → Hold
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-08-18	Initiated	Northland Capital	Outperform
Sep-26-16	Initiated	H.C. Wainwright	Buy
Sep-04-15	Initiated	Canaccord Genuity	Buy
Aug-24-15	Initiated	Piper Jaffray	Overweight
Aug-24-15	Initiated	Stifel	Buy

View All

Vtv Therapeutics Inc Stock (VTVT) Latest News

Apr 22, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Apr 22, 2025

Apr 16, 2025

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World

Apr 16, 2025

Apr 12, 2025

vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN

Apr 12, 2025

Apr 11, 2025

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World

Apr 11, 2025

Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World

Apr 11, 2025

Apr 09, 2025

HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target - MarketScreener

Apr 09, 2025

This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 09, 2025

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq

Apr 09, 2025

H.C. Wainwright sets $36 target for vTv Therapeutics stock By Investing.com - Investing.com Canada

Apr 09, 2025

vTv Therapeutics Inc Reports Q4 2024 EPS of -$0.55, Beating Esti - GuruFocus.com

Mar 21, 2025

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire

Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Nasdaq

Mar 21, 2025

Mar 20, 2025

VTv Therapeutics: Q4 Earnings Snapshot - CTPost

Mar 20, 2025

vTv Therapeutics: A New Dawn for Diabetes Treatment? - AInvest

Mar 20, 2025

VTv Therapeutics: Q4 Earnings Snapshot -March 20, 2025 at 06:02 pm EDT - Marketscreener.com

Mar 20, 2025

vTv Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025

FDA Greenlights vTv Diabetes Drug Trial as Cash Reserves Triple to $36.7M - StockTitan

Mar 20, 2025